KOL Perspectives on BTK Inhibitors in RA, 2018 Study - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 22, 2019--The “KOL Perspectives: BTK Inhibitors in RA” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.
In total, we conducted interviews with 10 KOLs -
KOL data is analyzed to produce -
Reasons to Buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nwftwp/kol_perspectives?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190222005097/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs
INDUSTRY KEYWORD: PROFESSIONAL SERVICES CONSULTING
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/22/2019 03:27 AM/DISC: 02/22/2019 03:27 AM